Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
XA-9111
- Development stage
- Preclinical
- Lead developer
- Xbiome
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
XA-9111 is a preclinical-stage live biotherapeutic product (LBP) consisting of a proprietary strain of *Bifidobacterium longum* subsp. *infantis* (specifically, strain CGMCC No. 26615). Developed by Xbiome, a Chinese microbiome therapeutics company, XA-9111 is being investigated for the treatment of autism spectrum disorder (ASD). The strain was originally isolated from fecal samples of a healthy, breastfed 5-month-old female infant in Shenzhen, China. In preclinical mouse models of autism (maternal immune activation [MIA] and BTBR mice), oral administration of XA-9111 significantly reduced repetitive behaviors (such as marble burying and self-grooming) and improved social interaction. Additionally, it was shown to reduce systemic inflammatory markers (IL-6 and TNF-alpha) and modulate brain neural activity.
- Other names
- Bifidobacterium longum strain XA-9111Bifidobacterium longum subsp. infantis CGMCC No. 26615Bifidobacterium longum subsp. infantis strain XA-9111
Beyond the preview
Go deeper on XA-9111.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on XA-9111.